Talazoparib and Enzalutamide: A Game-Changer for mCRPC

At ASCO GU 2025 Dr. Neeraj Agarwal presented groundbreaking findings from the TALAPRO-2 trial, showing that combining talazoparib with enzalutamide significantly improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In this MEDtalk he presents the study’s results that suggest the potential for a new standard treatment approach in mCRPC.